Cetuximab is an epidermal growth factor receptor (EGFR)-specific chimeric immunoglobulin G (IgG)1 isotype monoclonal antibody approved for the treatment of HNSCC (Figure 3). Here, EGFR is linked to head and neck squamous cell carcinoma.